Project Grant R41CA314641
Award Date 8/1/26
Completion Date 7/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- Federal Project Grant Award Summary Intra Therapeutics, LLC received a $398,039 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 18, 2025, with completion targeted for August 31, 2026. The award supports the development and optimization of XCSGEL-IL12, an injectable hydrogel-based immunotherapy designed for localized treatment of triple-negative breast cancer. The project focuses on formulating interleukin-12...
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...
- The National Cancer Institute awarded Nanocan Therapeutics Corporation $2,996,343 on September 24, 2025, to conduct the first clinical trial of the Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel for treatment of advanced cervical cancer under the Cancer Treatment Research program (CFDA 93.395). The LIFE gel is a biocompatible, biodegradable immunotherapeutic administered locally in conjunction with hypo-fractionated radiotherapy. The technology extends local radiotherapy's use from...
- The National Institutes of Health National Cancer Institute awarded Absco Therapeutics, Inc. $406,500 on September 17, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an intratumoral delivery system for enhancing solid tumor immunotherapy. Absco Therapeutics is advancing the Oncolymer platform, a thermoresponsive hydrogel technology based on PLGA and PEG polymer that transforms from room-temperature liquid to a solidified depot upon injection. The system delivers a...
- The National Cancer Institute awarded Rheotek Medical Inc. $1,045,569 under the Cancer Treatment Research program (CFDA 93.395) on September 1, 2026 for development of an ultra-precise needle delivery system for cutaneous cancer treatment. Rheotek Medical is developing the SoftTouch device, an automated intratumoral immunotherapy delivery system designed to address precision limitations in current manual injection methods for skin cancer. The device uses a miniaturized voice coil actuator to...
- The National Cancer Institute awarded Gigamune Inc. $800,000 on September 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentivector for enhanced in vivo delivery of T cell receptors for cell therapy targeting stage IV melanoma. The research project, titled "A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma" and led by principal investigator David Scott Johnson, Ph.D., aims to create an...
- Federal Project Grant Summary Ioncologi Inc. received a $276,544 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 1, 2025, with completion targeted for August 31, 2026. The award supports development of IOI7, an autologous, ex vivo-expanded immunomodulatory hematopoietic stem cell therapy designed to overcome immune checkpoint inhibitor resistance in relapsed or refractory glioblastoma. Phase 1 deliverables include...
- The National Cancer Institute awarded Cytoagents Inc. $1,313,567 on September 22, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and advance CTO1681, a pharmaceutical compound designed to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy. CTO1681 is an orally available compound that reduces transcription of proinflammatory cytokines implicated in cytokine release syndrome, a severe systemic inflammatory response...
- The National Cancer Institute awarded Vesicle Therapeutics Inc. $400,000 on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a targeted antisense oligonucleotide therapy for head and neck squamous cell carcinoma. Vesicle Therapeutics is synthesizing and evaluating a thiomorpholino-based antisense oligonucleotide designed to selectively inhibit the oncogenic STAT3A isoform while preserving the tumor-suppressive STAT3B isoform. The Phase I project...
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...